Sensius, a pioneer in precision thermotherapy for oncology, announced the successful completion of a €15 million funding round enabled by GrayBella Capital and UCEA Capital Partners, with participation from the EIC Fund and a syndicate of strategic investors. The investment marks a pivotal step forward in Sensius’ mission to transform the treatment of cancer through advanced thermal technologies.
The new funding will accelerate the initiation of international clinical trials aimed at validating the efficacy and safety of Sensius’ proprietary thermotherapy platform. These trials are designed to support regulatory approvals and facilitate global market adoption. Initially targeting Head and Neck cancers—where there is an urgent need for innovative therapeutic options—Sensius’ platform is also being developed to address other critical cancer indications, including breast cancer.
“Our mission is to revolutionize patient care through advanced thermotherapy technologies. This funding brings us closer to commercializing a new standard of care—one that enhances both outcomes and quality of life for patients worldwide. We are honored by the confidence shown in us by our investors and partners,” said Paul van den Biggelaar, CEO of Sensius.
Richard Kivel, Managing Director at GrayBella Capital and incoming Chairman of Sensius, added: “Our investment in Sensius reflects our commitment to supporting visionary teams developing high-impact technologies. The Sensius platform represents a paradigm shift in oncology treatment, with the potential to significantly improve survival rates and reduce treatment burden.”
Joao Teixeira, Chairman of UCEA said:
“We are proud to announce our investment in Sensius, a company at the forefront of innovative cancer treatment technologies. At UCEA Capital Partners, we are deeply committed to supporting visionary healthcare solutions that have the potential to transform patient outcomes on a global scale. Their groundbreaking approach to hyperthermia therapy represents a critical advancement in the fight against cancer, enhancing the efficacy of existing treatments while improving patient quality of life”.
